{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T17:33:35Z","timestamp":1783704815491,"version":"3.55.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,10]],"date-time":"2020-01-10T00:00:00Z","timestamp":1578614400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,10]],"date-time":"2020-01-10T00:00:00Z","timestamp":1578614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Heart Fail Rep"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s11897-019-00451-0","type":"journal-article","created":{"date-parts":[[2020,1,10]],"date-time":"2020-01-10T09:03:25Z","timestamp":1578647005000},"page":"1-8","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Heart Failure With Mid-range Ejection Fraction"],"prefix":"10.1007","volume":"17","author":[{"given":"Pratyaksh K.","family":"Srivastava","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey J.","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boback","family":"Ziaeian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregg C.","family":"Fonarow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,10]]},"reference":[{"issue":"12","key":"451_CR1","first-page":"e154","volume":"112","author":"SA Hunt","year":"2005","unstructured":"Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. ACC\/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005;112(12):e154\u2013235.","journal-title":"Circulation"},{"issue":"1","key":"451_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0002-9149(65)90615-6","volume":"15","author":"SH Bartle","year":"1965","unstructured":"Bartle SH, Sanmarco ME, Dammann JF. Ejected Fraction: An Index of Myocardial Function (abstr.). Am J Cardiol. 1965;15(1):1.","journal-title":"Am J Cardiol"},{"issue":"16","key":"451_CR3","first-page":"e240","volume":"128","author":"CW Yancy","year":"2013","unstructured":"\u2022 Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association task force on practice guidelines. Circulation. 2013;128(16):e240\u2013327 This reference first defined heart failure with borderline ejection fraction.","journal-title":"Circulation."},{"issue":"10","key":"451_CR4","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1002\/ejhf.159","volume":"16","author":"CS Lam","year":"2014","unstructured":"\u2022 Lam CS, Solomon SD. The middle child in heart failure: heart failure with mid-range ejection fraction (40-50%). Eur J Heart Fail. 2014;16(10):1049\u201355 This reference first coined the term, \u201cHeart Failure with Mid-Range Ejection Fraction\u201d.","journal-title":"Eur J Heart Fail"},{"issue":"27","key":"451_CR5","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)developed with the special contribution of the heart failure association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129\u2013200.","journal-title":"Eur Heart J"},{"issue":"10","key":"451_CR6","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1161\/CIR.0000000000000659","volume":"139","author":"EJ Benjamin","year":"2019","unstructured":"Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke Statistics-2019 update: a report from the American Heart Association. Circulation. 2019;139(10):e56\u2013e528.","journal-title":"Circulation."},{"issue":"20","key":"451_CR7","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1016\/j.jacc.2017.08.074","volume":"70","author":"KS Shah","year":"2017","unstructured":"\u2022 Shah KS, Xu H, Matsouaka RA, Bhatt DL, Heidenreich PA, Hernandez AF, et al. Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes. J Am Coll Cardiol. 2017;70(20):2476\u201386 This reference provides descriptions of the epidemiology, clinical characteristics and long-term outcomes for those with Heart Failure with Mid-Range Ejection Fraction in large population-based cohorts.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"451_CR8","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.jacc.2007.04.064","volume":"50","author":"GC Fonarow","year":"2007","unstructured":"Fonarow GC, Stough WG, Abraham WT, Albert NM, Gheorghiade M, Greenberg BH, et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF registry. J Am Coll Cardiol. 2007;50(8):768\u201377.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"451_CR9","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/j.amjcard.2007.12.014","volume":"101","author":"NK Sweitzer","year":"2008","unstructured":"Sweitzer NK, Lopatin M, Yancy CW, Mills RM, Stevenson LW. Comparison of clinical features and outcomes of patients hospitalized with heart failure and normal ejection fraction (> or =55%) versus those with mildly reduced (40% to 55%) and moderately to severely reduced (<40%) fractions. Am J Cardiol. 2008;101(8):1151\u20136.","journal-title":"Am J Cardiol"},{"issue":"8","key":"451_CR10","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1002\/ejhf.1149","volume":"20","author":"LH Lund","year":"2018","unstructured":"\u2022 Lund LH, Claggett B, Liu J, Lam CS, Jhund PS, Rosano GM, et al. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. Eur J Heart Fail. 2018;20(8):1230\u20139 This reference provides data to support the use of traditional HFrEF therapies in those with HFmrEF.","journal-title":"Eur J Heart Fail"},{"issue":"12","key":"451_CR11","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1002\/ejhf.945","volume":"19","author":"AS Koh","year":"2017","unstructured":"\u2022 Koh AS, Tay WT, Teng THK, Vedin O, Benson L, Dahlstrom U, et al. A comprehensive population-based characterization of heart failure with mid-range ejection fraction. Eur J Heart Fail. 2017;19(12):1624\u201334 This reference provides descriptions of the epidemiology, clinical characteristics and long-term outcomes for those with Heart Failure with Mid-Range Ejection Fraction in large population-based cohorts.","journal-title":"Eur J Heart Fail"},{"issue":"12","key":"451_CR12","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1002\/ejhf.798","volume":"19","author":"P Rickenbacher","year":"2017","unstructured":"\u2022 Rickenbacher P, Kaufmann BA, Maeder MT, Bernheim A, Goetschalckx K, Pfister O, et al. Heart failure with mid-range ejection fraction: a distinct clinical entity? Insights from the trial of intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF). Eur J Heart Fail. 2017;19(12):1586\u201396 This reference provides descriptions of the epidemiology, clinical characteristics and long-term outcomes for those with Heart Failure with Mid-Range Ejection Fraction in large population-based cohorts.","journal-title":"Eur J Heart Fail"},{"issue":"10","key":"451_CR13","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1002\/ejhf.807","volume":"19","author":"K Tsuji","year":"2017","unstructured":"\u2022 Tsuji K, Sakata Y, Nochioka K, Miura M, Yamauchi T, Onose T, et al. Characterization of heart failure patients with mid-range left ventricular ejection fraction-a report from the CHART-2 study. Eur J Heart Fail. 2017;19(10):1258\u201369 This reference provides descriptions of the epidemiology, clinical characteristics and long-term outcomes for those with Heart Failure with Mid-Range Ejection Fraction in large population-based cohorts.","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"451_CR14","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1002\/ehf2.12455","volume":"6","author":"NE Ibrahim","year":"2019","unstructured":"\u2022 Ibrahim NE, Song Y, Cannon CP, Doros G, Russo P, Ponirakis A, et al. Heart failure with mid-range ejection fraction: characterization of patients from the PINNACLE registry(R). ESC Heart Fail. 2019;6(4):784\u201392 This reference provides descriptions of the epidemiology, clinical characteristics and long-term outcomes for those with Heart Failure with Mid-Range Ejection Fraction in large population-based cohorts.","journal-title":"ESC Heart Fail"},{"issue":"12","key":"451_CR15","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1002\/ejhf.813","volume":"19","author":"O Chioncel","year":"2017","unstructured":"\u2022 Chioncel O, Lainscak M, Seferovic PM, Anker SD, Crespo-Leiro MG, Harjola VP, et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC heart failure long-term registry. Eur J Heart Fail. 2017;19(12):1574\u201385 This reference provides descriptions of the epidemiology, clinical characteristics and long-term outcomes for those with Heart Failure with Mid-Range Ejection Fraction in large population-based cohorts.","journal-title":"Eur J Heart Fail"},{"key":"451_CR16","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ijcard.2018.04.001","volume":"271","author":"KW Streng","year":"2018","unstructured":"Streng KW, Nauta JF, Hillege HL, Anker SD, Cleland JG, Dickstein K, et al. Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction. Int J Cardiol. 2018;271:132\u20139.","journal-title":"Int J Cardiol"},{"issue":"9169","key":"451_CR17","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","volume":"353","author":"MERIT-HF Study Group","year":"1999","unstructured":"MERIT-HF Study Group. Effect of metoprolol CR\/XL in chronic heart failure: Metoprolol CR\/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet. 1999;353(9169):2001\u20137.","journal-title":"Lancet."},{"issue":"9377","key":"451_CR18","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0140-6736(03)13800-7","volume":"362","author":"PA Poole-Wilson","year":"2003","unstructured":"Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European trial (COMET): randomised controlled trial. Lancet. 2003;362(9377):7\u201313.","journal-title":"Lancet."},{"issue":"5","key":"451_CR19","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1056\/NEJM199108013250501","volume":"325","author":"S Investigators","year":"1991","unstructured":"Investigators S, Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325(5):293\u2013302.","journal-title":"N Engl J Med"},{"issue":"23","key":"451_CR20","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","volume":"316","author":"Consensus Trial Study Group","year":"1987","unstructured":"Consensus Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316(23):1429\u201335.","journal-title":"N Engl J Med"},{"issue":"9386","key":"451_CR21","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","volume":"362","author":"CB Granger","year":"2003","unstructured":"Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-alternative trial. Lancet. 2003;362(9386):772\u20136.","journal-title":"Lancet."},{"issue":"1","key":"451_CR22","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"F Zannad","year":"2011","unstructured":"Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11\u201321.","journal-title":"N Engl J Med"},{"issue":"11","key":"451_CR23","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJ McMurray","year":"2014","unstructured":"McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993\u20131004.","journal-title":"N Engl J Med"},{"issue":"9744","key":"451_CR24","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","volume":"376","author":"K Swedberg","year":"2010","unstructured":"Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Dubost-Brama A, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376(9744):875\u201385.","journal-title":"Lancet."},{"issue":"7","key":"451_CR25","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.jchf.2017.04.007","volume":"5","author":"J Tromp","year":"2017","unstructured":"Tromp J, Khan MAF, Mentz RJ, O'Connor CM, Metra M, Dittrich HC, et al. Biomarker profiles of acute heart failure patients with a mid-range ejection fraction. JACC Heart Fail. 2017;5(7):507\u201317.","journal-title":"JACC Heart Fail."},{"issue":"12","key":"451_CR26","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1002\/ejhf.911","volume":"19","author":"A Gohar","year":"2017","unstructured":"Gohar A, Chong JPC, Liew OW, den Ruijter H, de Kleijn DPV, Sim D, et al. The prognostic value of highly sensitive cardiac troponin assays for adverse events in men and women with stable heart failure and a preserved vs. reduced ejection fraction. Eur J Heart Fail. 2017;19(12):1638\u201347.","journal-title":"Eur J Heart Fail"},{"key":"451_CR27","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ijcard.2019.08.040","volume":"296","author":"G Vergaro","year":"2019","unstructured":"Vergaro G, Aimo A, Prontera C, Ghionzoli N, Arzilli C, Zyw L, et al. Sympathetic and renin-angiotensin-aldosterone system activation in heart failure with preserved, mid-range and reduced ejection fraction. Int J Cardiol. 2019;296:91\u20137.","journal-title":"Int J Cardiol"},{"issue":"7","key":"451_CR28","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1093\/ehjci\/jez014","volume":"20","author":"NR Pugliese","year":"2019","unstructured":"Pugliese NR, Fabiani I, Santini C, Rovai I, Pedrinelli R, Natali A, et al. Value of combined cardiopulmonary and echocardiography stress test to characterize the haemodynamic and metabolic responses of patients with heart failure and mid-range ejection fraction. Eur Heart J Cardiovasc Imaging. 2019;20(7):828\u201336.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"9386","key":"451_CR29","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","volume":"362","author":"JJ McMurray","year":"2003","unstructured":"McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-added trial. Lancet. 2003;362(9386):767\u201371.","journal-title":"Lancet."},{"issue":"9386","key":"451_CR30","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","volume":"362","author":"S Yusuf","year":"2003","unstructured":"Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial. Lancet. 2003;362(9386):777\u201381.","journal-title":"Lancet."},{"issue":"1","key":"451_CR31","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1093\/eurheartj\/ehx564","volume":"39","author":"JGF Cleland","year":"2018","unstructured":"\u2022 Cleland JGF, Bunting KV, Flather MD, Altman DG, Holmes J, Coats AJS, et al. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. Eur Heart J. 2018;39(1):26\u201335 This reference provides data to support the use of traditional HFrEF therapies in those with HFmrEF.","journal-title":"Eur Heart J"},{"issue":"15","key":"451_CR32","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","volume":"370","author":"B Pitt","year":"2014","unstructured":"Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370(15):1383\u201392.","journal-title":"N Engl J Med"},{"issue":"5","key":"451_CR33","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1093\/eurheartj\/ehv464","volume":"37","author":"SD Solomon","year":"2016","unstructured":"\u2022 Solomon SD, Claggett B, Lewis EF, Desai A, Anand I, Sweitzer NK, et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J. 2016;37(5):455\u201362 This reference provides data to support the use of traditional HFrEF therapies in those with HFmrEF.","journal-title":"Eur Heart J"},{"issue":"17","key":"451_CR34","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","volume":"381","author":"SD Solomon","year":"2019","unstructured":"\u2022 Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, et al. Angiotensin-Neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381(17):1609\u201320 This reference provides data to support the use of traditional HFrEF therapies in those with HFmrEF.","journal-title":"N Engl J Med"},{"issue":"3","key":"451_CR35","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.ijcard.2014.03.005","volume":"173","author":"K Patel","year":"2014","unstructured":"Patel K, Fonarow GC, Ekundayo OJ, Aban IB, Kilgore ML, Love TE, et al. Beta-blockers in older patients with heart failure and preserved ejection fraction: class, dosage, and outcomes. Int J Cardiol. 2014;173(3):393\u2013401.","journal-title":"Int J Cardiol"},{"issue":"2","key":"451_CR36","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.jacc.2008.09.031","volume":"53","author":"AF Hernandez","year":"2009","unstructured":"Hernandez AF, Hammill BG, O'Connor CM, Schulman KA, Curtis LH, Fonarow GC. Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (organized program to initiate lifesaving treatment in hospitalized patients with heart failure) registry. J Am Coll Cardiol. 2009;53(2):184\u201392.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"451_CR37","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.jchf.2016.02.017","volume":"4","author":"JR Kapoor","year":"2016","unstructured":"Kapoor JR, Kapoor R, Ju C, Heidenreich PA, Eapen ZJ, Hernandez AF, et al. Precipitating clinical factors, heart failure characterization, and outcomes in patients hospitalized with heart failure with reduced, borderline, and preserved ejection fraction. JACC Heart Fail. 2016;4(6):464\u201372.","journal-title":"JACC Heart Fail"},{"issue":"6","key":"451_CR38","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1161\/CIRCHEARTFAILURE.111.966366","volume":"5","author":"SM Dunlay","year":"2012","unstructured":"Dunlay SM, Roger VL, Weston SA, Jiang R, Redfield MM. Longitudinal changes in ejection fraction in heart failure patients with preserved and reduced ejection fraction. Circ Heart Fail. 2012;5(6):720\u20136.","journal-title":"Circ Heart Fail"},{"issue":"11","key":"451_CR39","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.jacc.2011.11.040","volume":"59","author":"S Ather","year":"2012","unstructured":"Ather S, Chan W, Bozkurt B, Aguilar D, Ramasubbu K, Zachariah AA, et al. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol. 2012;59(11):998\u20131005.","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"451_CR40","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1093\/eurheartj\/ehr254","volume":"33","author":"Meta-analysis Global Group in Chronic Heart Failure","year":"2012","unstructured":"Meta-analysis Global Group in Chronic Heart Failure. The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur Heart J. 2012;33(14):1750\u20137.","journal-title":"Eur Heart J"},{"key":"451_CR41","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.ijcard.2017.03.032","volume":"240","author":"DA Pascual-Figal","year":"2017","unstructured":"Pascual-Figal DA, Ferrero-Gregori A, Gomez-Otero I, Vazquez R, Delgado-Jimenez J, Alvarez-Garcia J, et al. Mid-range left ventricular ejection fraction: clinical profile and cause of death in ambulatory patients with chronic heart failure. Int J Cardiol. 2017;240:265\u201370.","journal-title":"Int J Cardiol"},{"issue":"7","key":"451_CR42","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644\u201357.","journal-title":"N Engl J Med"},{"issue":"22","key":"451_CR43","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"key":"451_CR44","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019."},{"issue":"14","key":"451_CR45","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1161\/CIRCULATIONAHA.117.027324","volume":"135","author":"CS Lam","year":"2017","unstructured":"Lam CS, Solomon SD. Fussing over the middle child: heart failure with mid-range ejection fraction. Circulation. 2017;135(14):1279\u201380.","journal-title":"Circulation."},{"key":"451_CR46","doi-asserted-by":"crossref","unstructured":"Vedin O, Lam CSP, Koh AS, Benson L, Teng THK, Tay WT, et al. Significance of Ischemic Heart Disease in Patients With Heart Failure and Preserved, Midrange, and Reduced Ejection Fraction: A Nationwide Cohort Study. Circ Heart Fail. 2017;10(6).","DOI":"10.1161\/CIRCHEARTFAILURE.117.003875"},{"issue":"12","key":"451_CR47","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1002\/ejhf.879","volume":"19","author":"A Rastogi","year":"2017","unstructured":"Rastogi A, Novak E, Platts AE, Mann DL. Epidemiology, pathophysiology and clinical outcomes for heart failure patients with a mid-range ejection fraction. Eur J Heart Fail. 2017;19(12):1597\u2013605.","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"451_CR48","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/S0002-8703(03)00248-5","volume":"146","author":"JH McGowan","year":"2003","unstructured":"McGowan JH, Cleland JG. Reliability of reporting left ventricular systolic function by echocardiography: a systematic review of 3 methods. Am Heart J. 2003;146(3):388\u201397.","journal-title":"Am Heart J"}],"container-title":["Current Heart Failure Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-019-00451-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11897-019-00451-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-019-00451-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,16]],"date-time":"2022-04-16T15:41:04Z","timestamp":1650123664000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11897-019-00451-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,10]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["451"],"URL":"https:\/\/doi.org\/10.1007\/s11897-019-00451-0","relation":{},"ISSN":["1546-9530","1546-9549"],"issn-type":[{"value":"1546-9530","type":"print"},{"value":"1546-9549","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,10]]},"assertion":[{"value":"10 January 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"PKS and JJH have no conflicts of interest.BZ: Supported by the American Heart Association SDG 17SDG33630113 and the NIH\/National Center for Advancing Translational Science (NCATS) UCLA CTSI Grant Number KL2TR001882. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.GCF: Consulting for Abbott, Amgen, CHF Solutions, Janssen, Medtronic, Merck, and Novartis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with humans or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}